{"id":"W2905649019","doi":"10.1182/blood-2018-99-114409","title":"Avadomide (CC-122), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Rituximab; Medicine; Follicular lymphoma; Internal medicine; Obinutuzumab; Diffuse large B-cell lymphoma; Oncology; Refractory (planetary science); Gastroenterology; Lenalidomide; Tolerability; Lymphoma; Adverse effect; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006168282,0.000419959,0.0009251733,0.0002790156,0.0001763262,0.0005334571,0.0003908354,0.0002907022,0.001090555],"category_scores_gemma":[0.0006573861,0.0001894616,0.0009073417,0.0003861085,0.0001474305,0.0002895005,0.000190425,0.0005599569,0.0001792331],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008166646,"about_ca_system_score_gemma":0.0006968221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002137782,"about_ca_topic_score_gemma":0.00679081,"domain_scores_codex":[0.9997144,0.0001052324,0.00002708732,0.00006103163,0.00004445226,0.00004773199],"domain_scores_gemma":[0.9997415,0.00003492521,0.00006685185,0.00002229629,0.00002421456,0.0001102713],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3738257,0.006752538,0.2271726,0.002057883,0.0084245,0.001719289,0.0004924933,0.002900303,0.05782462,0.0003476024,0.006268601,0.3122139],"study_design_scores_gemma":[0.1566032,0.2077415,0.5894933,0.0004492875,0.01009124,0.003948726,0.0005935039,0.005643083,0.008344475,0.0006484034,0.01632344,0.0001197925],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943084,0.004081321,0.00007778971,0.00009973045,0.00001865754,0.0001539545,0.0003046445,0.0000154487,0.000940237],"genre_scores_gemma":[0.998154,0.0007183069,0.0001649488,0.0001420654,0.00002948734,0.00007056147,0.0004593934,0.000002633557,0.0002586149],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002137782,"threshold_uncertainty_score":0.005925298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01556837857548716,"score_gpt":0.2392458466910566,"score_spread":0.2236774681155694,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}